会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • DRUG COMBINATIONS
    • 药物组合
    • WO2007081232A1
    • 2007-07-19
    • PCT/PT2007/000002
    • 2007-01-15
    • PORTELA & CA., S.A.LEARMONTH, David AlexanderBELIAEV, AlexanderSOARES DA SILVA, Patrício Manuel Vieira Araújo
    • LEARMONTH, David AlexanderBELIAEV, AlexanderSOARES DA SILVA, Patrício Manuel Vieira Araújo
    • A61K31/4164A61P43/00
    • A61K31/4164
    • A combination comprising at least two components selected from: (i) compounds of formula I: R where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X signifies CH2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH2; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof; wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxy carbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group; the term halogen means fluorine, chlorine, bromine or iodine; and (ii) at least one compound from the following classes of compounds: diuretics; beta-adrenergic antagonists; alpha2-adrenergic agonists; alphal -adrenergic antagonists; dual beta- and alpha-adrenergic antagonists; calcium channel blockers; potassium channel activators; anti-arrhythmics; ACE inhibitors; ATI receptor antagonists; renin inhibitors; lipid lowerers, vasopeptidase inhibitors; nitrates; endothelin antagonists; neutral endopeptidase inhibitors; anti-angiotensin vaccines; vasodilators; phosphodiesterase inhibitors; cardiac glycosides; serotonin antagonists; and CNS acting agents.
    • 卤素,烷基,烷氧基,羟基,硝基,氨基,烷基羰基氨基,烷基氨基或烷基氨基,其中R 1,R 2和R 3相同或不同,表示氢, 二烷基氨基 R4表示氢,烷基或烷基芳基; X表示CH2,氧原子或硫原子; n为1,2或3,条件是当n为1时,X不为CH2; 和(S) - 对映异构体或其对映异构体及其药学上可接受的盐的混合物; 其中术语烷基是指含有1-6个碳原子的直链或支链的烃链,任选被芳基,烷氧基,卤素,烷氧基羰基或羟基羰基取代; 术语芳基是指任选被烷氧基,卤素或硝基取代的苯基或萘基; 术语卤素是指氟,氯,溴或碘; 和(ii)至少一种下列化合物类型的化合物:利尿剂; β-肾上腺素能拮抗剂; α2-肾上腺素能激动剂; α-肾上腺素能拮抗剂; 双重β-和α-肾上腺素能拮抗剂; 钙通道阻滞剂; 钾通道激活剂; 抗心律失常药; ACE抑制剂; ATI受体拮抗剂; 肾素抑制剂; 脂质降低剂,血管肽酶抑制剂; 硝酸盐; 内皮素拮抗剂; 中性内肽酶抑制剂; 抗血管紧张素疫苗; 血管扩张剂; 磷酸二酯酶抑制剂; 强心苷; 5-羟色胺拮抗剂 和CNS代理。
    • 8. 发明申请
    • CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION
    • 不对称加氢催化工艺
    • WO2009113891A1
    • 2009-09-17
    • PCT/PT2009/000012
    • 2009-03-13
    • BIAL - PORTELA & CA., S.A.BELIAEV, AlexanderLEARMONTH, David, AlexanderALMENA PEREA, Juan JoséGEIß, GerhardHITZEL, PatrickKADYROV, RenatVOIGTLAENDER, David
    • BELIAEV, AlexanderLEARMONTH, David, AlexanderALMENA PEREA, Juan JoséGEIß, GerhardHITZEL, PatrickKADYROV, RenatVOIGTLAENDER, David
    • C07D311/04
    • C07D311/04
    • A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral transition metal catalyst and a source of hydrogen, wherein: X is CH 2 , oxygen or sulphur; R 1 , R 2 and R 3 are the same or different and signify hydrogen, halogen, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group; and R 4 is alkyl or aryl, the transition metal catalyst comprising a chiral ligand having the formula wherein each R and R' independently represents alkyl, aryl, aralkyl, alkenyl, alkynyl, alkoxy, aryloxy, alkylthio, arylthio, unsubstituted or substituted cyclic moiety selected from a group consisting of monocyclic or polycyclic saturated or partially saturated carbocyclic or heterocyclic, aromatic or heteroaromatic rings said rings comprising from 4 to 8 atoms and comprising from 0 to 3 heteroatoms, wherein: the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means an aromatic or heteraromatic group, optionally substituted one or more times by alkyl, alkyloxy, halogen or nitro group; and the term halogen means fluorine, chlorine, bromine or iodine.
    • 一种制备式A化合物的S或R对映异构体的方法,该方法包括在手性过渡金属催化剂和氢源的存在下使式B的化合物进行不对称氢化,其中:X是CH 2,氧 或硫磺; R1,R2和R3相同或不同,表示氢,卤素,烷基,烷氧基,羟基,硝基,烷基羰基氨基,烷基氨基或二烷基氨基; 所述过渡金属催化剂包含具有下式的手性配体:其中每个R和R'独立地表示烷基,芳基,芳烷基,烯基,炔基,烷氧基,芳氧基,烷硫基,芳硫基,未取代或取代的环状部分 来自由单环或多环饱和或部分饱和的碳环或杂环芳族或杂芳环组成的组,所述环包含4至8个原子并包含0至3个杂原子,其中:术语烷基是指直链或支链的含有 1-6个碳原子,任选被芳基,烷氧基,卤素,烷氧基羰基或羟基羰基取代; 术语芳基是指芳族或杂芳基,任选被烷基,烷氧基,卤素或硝基取代一次或多次; 术语卤素是指氟,氯,溴或碘。